New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 2, 2014
07:09 EDTISISIsis Pharmaceuticals reports final Phase 2 data on ISIS-APOCIIIRx
Isis Pharmaceuticals announced the final data from its Phase 2 study of ISIS-APOCIIIRx as a monotherapy in patients with familial chylomicronemia syndrome, or FCS. In this open-label study, three patients with FCS treated with ISIS-APOCIIIRx achieved substantial reductions in triglycerides with all three patients achieving a triglyceride level below 500 mg/dL, which substantially reduces the risk of an acute pancreatitis event. In addition, significant reductions in chylomicrons were observed that correlated with reductions in triglyceride levels.
News For ISIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2015
09:32 EDTISISJPMorgan Smid biotech analysts hold an analyst/industry conference call
Subscribe for More Information
April 22, 2015
16:25 EDTISISIsis Pharmaceuticals reports positive data from ISIS-TTR Rx
Subscribe for More Information
April 20, 2015
07:20 EDTISISAmerican Association for Cancer Research to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use